Cat. No.: HY-N0022

Isoacteoside

(Synonyms: Isoverbascoside)

7 Cited Publications

Avis client

Based on 7 publication(s) in Google Scholar

Isoacteoside is a natural product that can significantly inhibit the formation of glycation end products. Isoacteoside regulates the AKT/PI3K/m-TOR/NF-κB signaling pathway, induces apoptosis in OVCAR-3 cell. Isoacteoside exhibits antitumor, anti-inflammatory, anti-obesity and neuroprotective activities.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.54%
CAS No.: 61303-13-7
Formule: C₂₉H₃₆O₁₅
Masse moléculaire:624.59

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Isoacteoside Chemical Structure

CAS No.: 61303-13-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform mTOR :

Voir tous les produits spécifiques à Isoform PI3K :

Voir tous les produits spécifiques à Isoform NO Synthase :

Voir tous les produits spécifiques à Isoform COX :

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform Toll-like Receptor (TLR) :

Cellular Effect

Cell Line	Type	Value	Description	References
HEp-2	EC₅₀	0.17 μg/mL Compound: 2, isoverbascoside	Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	EC₅₀	0.62 μg/mL Compound: 2, isoverbascoside	Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	1.1 μg/mL Compound: 2, isoverbascoside	Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
HEp-2	IC₅₀	125 μg/mL Compound: 2, isoverbascoside	Cytotoxicity against human Hep2 cells administered 3 hrs postinfection Cytotoxicity against human Hep2 cells administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	IC₅₀	27 μg/mL Compound: 2, isoverbascoside	Cytotoxicity against HSV2 infected human Hep2 cells after 3 days Cytotoxicity against HSV2 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	30 μg/mL Compound: 2, isoverbascoside	Cytotoxicity against HSV1 infected human Hep2 cells after 3 days Cytotoxicity against HSV1 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	51.4 μg/mL Compound: 2, isoverbascoside	Cytotoxicity against RSV long infected human Hep2 cells after 3 days Cytotoxicity against RSV long infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	75 μg/mL Compound: 2, isoverbascoside	Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	89 μg/mL Compound: 2, isoverbascoside	Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days	[PMID: 9599250]
Hepatocyte	IC₅₀	5.3 μM Compound: 6	Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay Hepatoprotective activity in ddY mouse primary cultured hepatocytes assessed as inhibition of D-galactosamine-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
L929	IC₅₀	22.7 μg/mL Compound: 6	Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay Cytoprotective activity in mouse L929 cells assessed as inhibition of TNF-alpha-induced cytotoxicity after 44 hrs by MTT assay	[PMID: 20159656]
P388	ED₅₀	10 μg/mL Compound: 2	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 2380718]
Peritoneal macrophage cell	IC₅₀	>100 μM Compound: 6	Inhibition of LPS-induced nitric oxide production in ddY mouse peritoneal macrophages Inhibition of LPS-induced nitric oxide production in ddY mouse peritoneal macrophages	[PMID: 20159656]
Peritoneal macrophage cell	IC₅₀	>100 μM Compound: 6	Inhibition of LPS-induced TNFalpha production in ddY mouse peritoneal macrophages Inhibition of LPS-induced TNFalpha production in ddY mouse peritoneal macrophages	[PMID: 20159656]

In Vitro

Isoacteoside (20-80 μM, 24 h) inhibits the expression of iNOS and COX-2 in RAW264.7, inhibits LPS (HY-D1056)-induced release of TNF-α, IL-6, and IL-1β, as well as the activation of NF-κB^[2].
Isoacteoside (15-30 μM, 24-48 h) inhibits the proliferation, invasion and migration of cancer cell OVCAR-3 (IC₅₀=15 μM), arrests the cell cycle at sub-G1 phase, and induces the generation of ROS^[3].
Isoacteoside (15-30 μM, 48 h) inhibits the phosphorylation of AKT, mTOR, p38 MAPK, and PI3K without affecting their total protein expression^[2]^[3].
Isoacteoside (75-150 μM, 24-48 h) reduces the formation of lipid droplets and inhibits the expression of genes and proteins related to adipogenesis and lipid synthesis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

OVCAR-3
Concentration:

15-30 μM
Incubation Time:

24 h
Result:

Inhibited p-AKT, p-mTOR and p-PI3K.

Real Time qPCR^[4]

Cell Line:

3T3-L1
Concentration:

75-150 μM
Incubation Time:

24-48 h
Result:

Reduced the expression of PPARγ, C/EBPα and PLIN1.

In Vivo

Isoacteoside (25-100 mg/kg, ip, single dose) exhibits anti-inflammatory efficacy in mouse xylene-induced ear edema models, LPS (HY-D1056)-induced endotoxin shock models, and LPS (HY-D1056)-induced acute kidney injury (AKI) models^[2].
Isoacteoside (30 mg/kg, ip, three times a week for 5 weeks) exhibits antitumor efficacy in mouse OVCAR-3 xenograft models^[3].
Isoacteoside (2.5-5 mg/kg, icv for 15 days) exhibits neuroprotective effect against Aβ 1-42-induced neurotoxicity and cognitive impairment in SD rats models^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Acute kidney injury (AKI) model^[2]
Dosage:

25-100 mg/kg
Administration:

ip, single dose
Result:

Ameliorated LPS induced acute kidney injury.

Animal Model:

Mouse OVCAR-3 xenograft model^[3]
Dosage:

30 mg/kg
Administration:

ip, three times a week for 5 weeks
Result:

Reduced the tumor weight and volume.

Animal Model:

Aβ 1-42 induced neurotoxicity in Sprague-Dawley rats models^[5]
Dosage:

2.5-5 mg/kg
Administration:

icv for 15 days
Result:

Increased the exploratory behavior, shortened the escape latency.

Chemical Information

CAS No. 61303-13-7
Appearance Solid
Masse moléculaire 624.59
Formule C₂₉H₃₆O₁₅
Color White to yellow
SMILES

OC1=CC(/C=C/C(OC[C@@H]2[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](OCCC4=CC=C(O)C(O)=C4)O2)=O)=CC=C1O
Synonyms

Isoverbascoside
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Polyphenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (7)

All WBRT-PCRCell Proliferation/Viability AssayCell Migration/Invasion AssayFlow Cytometry

Sort by:

Journal Impact Factor

Autophagy

XIAP-ULK1-Mediated mitophagy modulates carnitine metabolism to mitigate diabetic kidney disease. [Abstract]

2025 Oct 25. PMID: 41139215
Commun Biol

Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism. [Abstract]

2025 Feb 8;8(1):205. PMID: 39922943

Isoacteoside purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Feb 8;8(1):205. [Abstract]

The effect of Isoacteoside on PDHB expression in hepatocellular carcinoma cells was detected by Western blot.

Isoacteoside purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Feb 8;8(1):205. [Abstract]

The IC50 value of HepG2 cells after Isoacteoside treatment was determined using a cytotoxicity assay.

Isoacteoside purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Feb 8;8(1):205. [Abstract]

The effect of Isoacteoside on the invasive ability of hepatocellular carcinoma cells was detected using the Transwell chamber invasion assay.

Isoacteoside purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Feb 8;8(1):205. [Abstract]

Flow cytometry was used to detect the effects of Isoacteoside(30 mg/kg), sorafenib monotherapy, and combination therapy on apoptosis in liver cancer cells.
Appl Biol Chem

23 May 2022.
Neurotox Res

Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]

2026 Mar 19;44(2):12. PMID: 41854817
Behav Brain Funct

Isoacteoside alleviates LPS-induced depressive-like behaviors in mice by inhibiting neuroinflammation through regulating microglial polarization and oxidative stress. [Abstract]

2025 Sep 29;21(1):30. PMID: 41024195

Isoacteoside purchased from MedChemExpress. Usage Cited in: Behav Brain Funct. 2025 Sep 29;21(1):30. [Abstract]

ISO (Isoacteoside: 40 mg/kg) modulated microglia polarization in mice showing depressive-like behaviors. A Expression of M2 microglia markers (YM, CD206 and Arg-1) in the hippocampus of different groups determined by qPCR.
Patent

US20210177023A1.
Patent

US20210085739A1.

Solvant et solubilité

In Vitro:

DMSO : 175 mg/mL (280.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 100 mg/mL (160.11 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6011 mL

8.0053 mL

16.0105 mL

5 mM

0.3202 mL

1.6011 mL

3.2021 mL

10 mM

0.1601 mL

0.8005 mL

1.6011 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: ≥ 10 mg/mL (16.01 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Yu SY, et al. Caffeoylated phenylpropanoid glycosides from Brandisia hancei inhibit advanced glycation end product formation and aldose reductase in vitro and vessel dilation in larval zebrafish in vivo. Planta Med. 2013 Dec;79(18):1705-9. [Content Brief]

[2]. Gao H, Cui Y, Kang N, et al. Isoacteoside, a dihydroxyphenylethyl glycoside, exhibits anti-inflammatory effects through blocking toll-like receptor 4 dimerization. Br J Pharmacol. 2017;174(17):2880-2896. [Content Brief]

[3]. Yang X, Guo F, Peng Q, Liu Y, Yang B. Suppression of in vitro and in vivo human ovarian cancer growth by isoacteoside is mediated via sub-G1 cell cycle arrest, ROS generation, and modulation of AKT/PI3K/m-TOR signalling pathway. J BUON. 2019;24(1):285-290. [Content Brief]

[4]. Choi C G, et al. Anti-obesity effects of isoacteoside on 3T3-L1 adipocytes[J]. Applied Biological Chemistry, 2022, 65(1): 33.

[5]. Shiao YJ, et al., Acteoside and Isoacteoside Protect Amyloid β Peptide Induced Cytotoxicity, Cognitive Deficit and Neurochemical Disturbances In Vitro and In Vivo. Int J Mol Sci. 2017 Apr 24;18(4):895. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.6011 mL	8.0053 mL	16.0105 mL	40.0263 mL
	5 mM	0.3202 mL	1.6011 mL	3.2021 mL	8.0053 mL
	10 mM	0.1601 mL	0.8005 mL	1.6011 mL	4.0026 mL
	15 mM	0.1067 mL	0.5337 mL	1.0674 mL	2.6684 mL
	20 mM	0.0801 mL	0.4003 mL	0.8005 mL	2.0013 mL
	25 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6011 mL
	30 mM	0.0534 mL	0.2668 mL	0.5337 mL	1.3342 mL
	40 mM	0.0400 mL	0.2001 mL	0.4003 mL	1.0007 mL
	50 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8005 mL
	60 mM	0.0267 mL	0.1334 mL	0.2668 mL	0.6671 mL
	80 mM	0.0200 mL	0.1001 mL	0.2001 mL	0.5003 mL
	100 mM	0.0160 mL	0.0801 mL	0.1601 mL	0.4003 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Isoacteoside

7 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Isoacteoside

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library